UAMOCS provides a multidimensional understanding of AML heterogeneity and stratifies subjects into three cohorts: (a) UAMOCS1 [high lymphocyte activating 3 (LAG3) expression, chromosome instability, myelodysplasia‐related mutations]; (b) UAMOCS2 (monocytic‐like profile, immune suppression and activated angiogenesis and hypoxia pathways); and (c) UAMOCS3 [CCAAT enhancer binding protein alpha (CEBPA) mutations and MYC pathway activation]. The gene discussed is MYC; the disease is Myelodysplasia.